A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural ...

A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program ...

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic, were linked to a 33% lower risk of ...

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

According to the Washington Post, 13 states currently cover the drugs for Medicaid patients, while Medicare prohibits ...

State Medicaid programs already are allowed to offer GLP-1 drugs for weight loss, but only 13 state programs currently do so. Meanwhile, Medicare currently covers GLP-1 drugs for people with a ...

Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under ...

Government programs may soon change how they approach a growing public health challenge that affects millions of Americans each year.